Back to Journals » Cancer Management and Research » Volume 12

Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer

Authors Cheng Y, Chen Y, Zang G, Chen B, Yao J, Zhang W, Wang H, Yu L, He P, Zhang Y, Wu H

Received 21 November 2019

Accepted for publication 20 February 2020

Published 13 March 2020 Volume 2020:12 Pages 1941—1946


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Rudolph Navari

Yuanjun Cheng, 1 Yongbing Chen, 2 Guohui Zang, 1 Bin Chen, 1 Jie Yao, 1 Wenguang Zhang, 1 Haibing Wang, 1 Liu Yu, 1 Pinghai He, 1 Youming Zhang, 1 Hanqing Wu 1

1Department of Cardiothoracic Surgery, People’s Hospital of Chizhou, Chizhou, People’s Republic of China; 2Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China

Correspondence: Yuanjun Cheng
3 Baiya Road, Guichi District, Chizhou 247000, Anhui Province, People’s Republic of China

Background: The most common cancer among humans is lung cancer. Non-small cell lung cancer (NSCLC) comprises the majority of these cases. In the development and progression of cancers across the spectrum, tumor abnormal protein (TAP) plays crucial roles. Additionally, in the advancement of the bladder and colorectal cancers, the involvement of glycoproteins like TAP is present. However, it is worth noting that current literature has yet to clarify the clinical significance of the TAP in NSCLC.
Methods: In the present study, to evaluate the relative level of TAP, we utilized a TAP detection agent in 154 cases of NSCLC and normal patients who underwent surgical resection anytime from March 2013 to January 2019 at the People’s Hospital of Chizhou.
Results: Our results demonstrated that in NSCLC patients, the expression level of TAP was significantly higher than in normal patients. Moreover, after surgery, TAP expression was significantly downregulated in NSCLC patients. TAP expression is associated with an array of factors, which include the patient’s sex, history of smoking use, tumor size, pTNM, distant cancer, metastasis of lymph nodes, invasive and aggressive indicator pleural invasion, and differentiation degree of NSCLC. Additionally, TAP has no association with the patient’s age, history of drinking, location of the tumor, hypertension, and diabetes. In NSCLC patients, a poor overall survival rate within 5 years is significantly correlated with the increased TAP expression. For NSCLC patients, an independent prognostic factor is the TAP, which is confirmed using the multivariate survival analysis.
Conclusion: In the malignant progression of NSCLC, our results demonstrate how the promoting role of the upregulated TAP expression takes place. Hence, a therapeutic aim for NSCLC and a potential biomarker for NSCLC progress is a TAP.

Keywords: tumor abnormal protein, TAP, lung, cancer, prognosis, predictive

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]